← Leaderboards
Xu Wu
Massachusetts General Hospital
$5,954,319
Attributed
$10,366,152
Total exposure
6
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.5M · FY2014–25$2M$1.5M$1M$500K$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$10,366,152 · 6
By mechanism
R01$9,709,007 · 5
UG3$657,145 · 1
Top collaborators
- Xuelian Luo5 shared
- Junhao Mao5 shared
- Bin Zheng5 shared
- Shugeng Cao2 shared
- Xin Chen2 shared
- Xiaochen Bai1 shared
Most similar at Massachusetts General Hospital
Same institution · by research overlap
- Georg Michael Lauer$24,583,765
- Raymond T Chung$38,306,004
- Arthur Y Kim$8,139,557
- Todd M Allen$28,600,717
- Bruce D Walker$50,324,331
Others in their field
Top investigators on “In Vitro”
- David Heimbrook · Leidos Biomedical Research, Inc.$553,787,942
- Leonard Freedman · Leidos Biomedical Research, Inc.$310,441,779
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- Lynn Briscoe · Leidos Biomedical Research, Inc.$94,686,873
- Dennis R. Burton · Scripps Research Institute$79,204,175
Research focus
In VitroPlayTumorigenesisIn VivoPathway InteractionsGenetic TranscriptionRegulationBindingSmall Molecule InhibitorSignal TransductionProteinsTranscription CoactivatorTranscription FactorPalmitoylationMediatingStructureComplexSmall MoleculeMalignant NeoplasmsBaseCancer CellPalmitatesFatty AcidsPost-Translational Protein Processing
Grant awards (23)
Novel regulation and functions of TEAD-VGLL complex$680,594
R01 · FY2025 · CA · contact PI
Discovery of novel natural TEAD inhibitors for the chemoprevention of liver tumors$322,891
UG3 · FY2025 · CA
Discovery of novel natural TEAD inhibitors for the chemoprevention of liver tumors$334,254
UG3 · FY2024 · CA
Targeting dynamic palmitoylation of TEAD transcription factors$536,986
R01 · FY2023 · CA · contact PI
Targeting Hippo pathway in melanoma$518,652
R01 · FY2023 · CA · contact PI
Targeting dynamic palmitoylation of TEAD transcription factors$536,984
R01 · FY2022 · CA · contact PI
Targeting Hippo pathway in melanoma$518,652
R01 · FY2022 · CA · contact PI
Targeting dynamic palmitoylation of TEAD transcription factors$547,945
R01 · FY2021 · CA · contact PI
Targeting Hippo pathway in melanoma$529,237
R01 · FY2021 · CA · contact PI
Targeting dynamic palmitoylation of TEAD transcription factors$547,945
R01 · FY2020 · CA · contact PI
Targeting Hippo pathway in melanoma$529,237
R01 · FY2020 · CA · contact PI
Chemical approach to study autopalmitoylation of transcription factors$378,270
R01 · FY2020 · DK · contact PI
Targeting dynamic palmitoylation of TEAD transcription factors$564,944
R01 · FY2019 · CA · contact PI
Targeting Hippo pathway in melanoma$529,237
R01 · FY2019 · CA · contact PI
Chemical approach to study autopalmitoylation of transcription factors$378,270
R01 · FY2019 · DK · contact PI
Chemical approach to study autopalmitoylation of transcription factors$378,270
R01 · FY2018 · DK · contact PI
Metabolic regulation of cellular junction proteins$352,307
R01 · FY2018 · CA · contact PI
Chemical approach to study autopalmitoylation of transcription factors$378,270
R01 · FY2017 · DK · contact PI
Metabolic regulation of cellular junction proteins$352,307
R01 · FY2017 · CA · contact PI
Chemical approach to study autopalmitoylation of transcription factors$393,979
R01 · FY2016 · DK · contact PI
Metabolic regulation of cellular junction proteins$352,307
R01 · FY2016 · CA · contact PI
Metabolic regulation of cellular junction proteins$352,307
R01 · FY2015 · CA · contact PI
Metabolic regulation of cellular junction proteins$352,307
R01 · FY2014 · CA · contact PI